Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C-Reference-Cited by-同舟云学术

Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C

Published:2011-06-09 Issue:17 Volume:20 Page:3507-3516
ISSN:1460-2083
Container-title:Human Molecular Genetics
language:en
Short-container-title:

Author:

Tanaka Yasuhito,Kurosaki Masayuki,Nishida Nao,Sugiyama Masaya,Matsuura Kentaro,Sakamoto Naoya,Enomoto Nobuyuki,Yatsuhashi Hiroshi,Nishiguchi Shuhei,Hino Keisuke,Hige Shuhei,Itoh Yoshito,Tanaka Eiji,Mochida Satoshi,Honda Masao,Hiasa Yoichi,Koike Asako,Sugauchi Fuminaka,Kaneko Shuichi,Izumi Namiki,Tokunaga Katsushi,Mizokami Masashi

Publisher

Oxford University Press (OUP)

Subject

Genetics(clinical),Genetics,Molecular Biology,General Medicine

Reference36 articles.

1. Global burden of disease (GBD) for hepatitis C;Global Burden of Hepatitis C Working Group;J. Clin. Phamacol.,2004

2. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan;Shiratori;Hepatology,1995

3. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C;Yoshida;Gut,2004

4. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients;George;Hepatology,2009

5. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection;Fried;N. Engl. J. Med.,2002

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance);The Pharmacogenomics Journal;2024-03-04

2. An ITPA Enzyme with Improved Substrate Selectivity;The Protein Journal;2023-12-08

3. DDRGK1 Enhances Osteosarcoma Chemoresistance via Inhibiting KEAP1‐Mediated NRF2 Ubiquitination;Advanced Science;2023-03-25

4. Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies;Frontiers in Pharmacology;2022-02-18

5. Prognostic Genetic Markers for Thrombosis in COVID-19 Patients: A Focused Analysis on D-Dimer, Homocysteine and Thromboembolism;Frontiers in Pharmacology;2020-12-09